Keine Story von AOP Orphan Pharmaceuticals AG mehr verpassen.

AOP Orphan Pharmaceuticals AG

  • 19.07.2004 – 13:37

    AOP Orphan Pharmaceuticals AG obtains Thromboreductin® registrations in Central Europe

    Vienna, Austria (ots) - AOP Orphan Pharmaceuticals, manufacturer and product developer of Thromboreductin®, announces that it has achieved its intermediate goal to make Thromboreductin® available in the European Union by means of an ambitious GCP compliant clinical trial programme. Thromboreductin is the first Anagrelide containing medicinal product approved ...